Covilance, LLC, 2723 Sequoia Way, Belmont, CA, 94002, USA.
TB Alliance, New York, NY, USA.
Ther Innov Regul Sci. 2023 Jul;57(4):865-874. doi: 10.1007/s43441-023-00518-0. Epub 2023 Apr 17.
Safety clinicians have a wealth of resources describing how to perform signal detection. Nevertheless, there are some nuances concerning approaches taken by regulatory authorities and statistical considerations that should be appreciated. New approaches, such as the FDA Medical Queries, illustrate the value of considering medical concepts over individual adverse events. One area which would benefit from further clarity is how safety signals may be evaluated for evidence of a causal relationship to the drug of interest. Just as such safety signals can take many forms, the types of tools and methods required to interrogate these signals are equally as diverse. An understanding of the complexity of this process can aid the safety reviewer in successfully characterizing the emerging safety profile of a drug during the pre-marketing phase of development.
安全临床医生有丰富的资源来描述如何进行信号检测。然而,监管机构采取的方法和统计考虑因素存在一些细微差别,应该予以重视。新方法,如 FDA 医疗查询,说明了考虑医学概念而不是个别不良事件的价值。有一个领域需要进一步明确,就是如何评估药物安全性信号与药物之间因果关系的证据。正如安全性信号可以有多种形式一样,用于检测这些信号的工具和方法的类型也同样多种多样。了解这个过程的复杂性可以帮助安全性审查员在药物开发的上市前阶段成功描述药物的新出现的安全性概况。